Media Release

Acquisition of Plot No. N 31

Unit belongs to Abhinandan Rasayan Pvt. Ltd.

Acquisition restricted to movable and immovable properties (assets)

Target company in same line of business as Lasa Supergenerics

Mumbai, Arpil 1, 2018: Lasa Supergenerics Limited (BSE: 540702, NSE: LASA), pioneer and amongst the leading player in manufacturing of Veterinary APIs in India through its catalyst chemistry expertise and fully backward integrated unit, has entered into agreement to purchase the Property of unit N 31 from its owner viz., Abhinandan Rasayan Private Limited (ARPL) having its fixed assets i.e. Land, Building, Plant & Machinery along with all movable & immovable assets in the property situated in MIDC, Anand Nagar, Ambernath (E), Thane. With this acquisition, Lasa took another step towards achieving its long term goal. Abhinandan N 31 is a state of the art unit, engaged in manufacturing Human and Veterinary APIs. It lacks backward integration and process novelties. Lasa with its core strength of Catalytical Chemistry and backward integration is in a strong position to take the business of exiting APIs from N 31 to new heights.

Management Comments:

Commenting on the recent development, Mr. Omkar Herlekar, Chairman & Managing Director, Lasa Supergenerics Limited said:
"We are very pleased to inform that the long term growth plans of the Company can be fulfilled by a combination of both organic and inorganic means. The target of current acquisition is in the same line of business, involved in the manufacturing of Human and Vet APIs, but lacks backward integration and process expertise. Lasa with its strength of backward integration and catalytical process can utilise the acquired facilities with greater efficiencies. This is strategic in nature and will result in huge gains for Lasa. At the outset, I would like to thank the entire team of 'LASA' for their untiring efforts, hard work, sincerity and high dedication. Also, I would like to thank our valued Shareholders, whose support and faith in our Company has given us the determination and ambition to go from strength to strength."

About Lasa Supergenerics Limited:

Lasa Supergenerics Limited is a globally well trusted brand with high quality products, accepted by large companies across the globe. The Company is a pioneer and amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. It specializes in 'catalyst chemistry' and manufactures anthelmintic / veterinary API. To efficiently control the supply chain, the company has backward integrated its key molecules. The Company has its unit with state of art manufacturing facilities located at Mahad & Chiplun, Maharashtra. The Company exports APIs to counties like Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea, Pakistan etc.

For more details please visit: www.lasalabs.com

For any Investor Relations query, please contact:

Dr. Omkar Herlekar	*Amit Sharma*
Chairman & MD	*Bridge Investor Relations Pvt. Ltd.*
Lasa Supergenerics Limited	*Phone: +91-22-26873003*
Email: investor@lasalabs.com	*Email: amit@bridge-ir.com*

Note: *Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other risk factors, viewers are cautioned not to place undue reliance on these forward-looking statements. Lasa Supergenerics Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.*